Pfizer Provides Update on Phase 3 Study of Investigational Gene Therapy for Ambulatory Boys with Duchenne Muscular Dystrophy

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/19/2026

1. SPY
2. XENE
3. NUE
4. HUBS
5. AAPL
6. RTB
7. ONON
8. AZN
9. SPCX
10. TRMD

Go back to Pfizer Provides Update on Phase 3 Study of Investigational Gene Therapy for Ambulatory Boys with Duchenne Muscular Dystrophy
Pfizer Inc. (NYSE: PFE) Delayed: 27.66 +0.02 (0.07%)
Previous Close $27.64    52 Week High $37.39 
Open $27.64    52 Week Low $28.25 
Day High $27.66    P/E 16.76 
Day Low $27.34    EPS $1.65 
Volume 75,587,710       

Pfizer Inc. (NYSE: PFE) Delayed: 27.66 +0.02 (0.07%)
Previous Close $27.64    52 Week High $37.39 
Open $27.64    52 Week Low $28.25 
Day High $27.66    P/E 16.76 
Day Low $27.34    EPS $1.65 
Volume 75,587,710